Clinical trials: Human Papillomavirus (HPV)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Human Papilloma Virus
SDH of HPV Vaccine Completion
The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child.
- Trial name
- NCT03709602
- Where
- United States
- Volunteers
- 3,076 people
- Sponsor
- Duke University
HPV Infection, Cervical Cancer
Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women
The American Society for Colposcopy and Cervical Pathology (ASCCP) recommended HPV testing or co-cytology testing as the standard primary approach for cervical cancer (CC) screening, which is highly sensitive for detection of…
- Trial name
- NCT05570331
- Testing
- HPV integration test
- Where
- China
- Volunteers
- 2,200 people
- Sponsor
- Ding Ma
Infections, Papillomavirus
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741)…
- Trial name
- NCT01418937
- Testing
- CervarixTM (GSK580299)
- Where
- 5 sites in Brazil
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus-Related Cervical Carcinoma
An Intervention Promoting HPV Vaccination in Safety-net Clinics
This randomized controlled trial is designed to evaluate whether a behavioral intervention that includes three components: 1) reminder letters and education materials delivered before the clinic visit, 2) telephone recalls after…
- Trial name
- NCT01729429
- Testing
- HPV brochure, recall, reminders, General Adolescent Vaccine Brochure
- Where
- 2 sites in United States
- Volunteers
- 831 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Intraepithelial Neoplasia, Cervical Cancer
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer
- Trial name
- NCT02934724
- Testing
- Self sample from vagina, Self sample from the oral cavity, Questionnaire
- Where
- Norway
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Human Papillomavirus Infection
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection.
- Trial name
- NCT06491446
- Testing
- ABI-2280
- Where
- 24 sites in Australia, Kenya and 2 more
- Volunteers
- 141 people
- Sponsor
- Antiva Biosciences
Cervical Intraepithelial Neoplasia, Cervical Cancer
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04969445
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Jun Zhang
Papillomavirus Infections, HIV Infections
Oral Human Papillomavirus Infection in HIV-infected Men
Human papillomavirus (HPV)-infection belong to the most common sexually transmitted diseases worldwide. HIV-infected men having sex with men /MSM) are strongly associated with a higher prevalence of genitoanal HPV-infection, and…
- Trial name
- NCT00421486
- Testing
- Oral swabs for HPV-typing and high-risk HPV-determination
- Where
- 2 sites in Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Deutsche Luft und Raumfahrt
HIV Infections, Oral Squamous Cell Carcinoma
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
This is an exploratory qualitative study among People Living With HIV (PLWH) of diverse racial/ethnic and sexual and gender minority (SGM) identities to explore individual, interpersonal, and structural oral health equity factors…
- Conditions
- HIV Infections, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06055868
- Testing
- Group Meeting (Focus Group), Questionnaires
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- University of California, San Francisco
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus…
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- OPTIMA (NCT02258659)
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Chicago
Cervical Cancer, HPV
Elimisha HPV (Human Papillomavirus)
This research study aims to develop a stigma-responsive educational intervention which includes simplified scripts that provide clear messages about HPV and video aimed at addressing fears and misperceptions from a peer…
- Conditions
- Cervical Cancer, HPV, HIV, Stigma
- Trial name
- NCT05736588
- Testing
- Elimisha HPV
- Where
- Kenya
- Volunteers
- 963 people, healthy volunteers welcome
- Sponsor
- Duke University
Cervical Cancer
Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
This study evaluates the safety of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women of 9 to 30 years old and men of 9 to 17 years old and preliminarily explore the…
- Trial name
- NCT02888418
- Testing
- Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Squamous Intraepithelial Lesions of the Cervix, Human Papilloma Virus Infection
Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance
clinical trial comparing the regression rate after 12 months of histologically confirmed cervical intraepithelial lesions 1 in 2 parallel groups.
- Conditions
- Squamous Intraepithelial Lesions of the Cervix, Human Papilloma Virus Infection, Cervix Lesion
- Trial name
- PAPILOCARE (NCT04624568)
- Testing
- PAPILOCARE
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Since other genital infections enhance HIV susceptibility by inducing inflammation, the investigators study the relationship between the vaginal microbiota composition and the risk of HPV infection, cervical cytological…
- Trial name
- NCT03548740
- Testing
- Human Papillomavirus
- Where
- China
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Oropharyngeal Neoplasms
Human Papillomavirus and Oropharynx Carcinoma
High risk papillomavirus (HR-HPV) have an oncogenic role in Oropharyngeal squamous cell carcinomas (OP-SCC) in at least 25% of the cases and the prevalence is increasing.
- Trial name
- Papillophar (NCT00918710)
- Where
- France
- Volunteers
- 362 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals
Cervical Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer. PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well…
- Conditions
- Cervical Cancer, Nonneoplastic Condition, Precancerous Condition
- Trial name
- NCT00667563
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, DNA analysis, polymerase chain reaction
- Where
- India
- Volunteers
- 150 people
- Sponsor
- AIDS Malignancy Consortium
Human Papillomavirus Vaccines, Adverse Effect
Study on the Epidemiological Characteristics of Female HPV Vaccination in China
Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, studies have confirmed that carcinogenic…
- Conditions
- Human Papillomavirus Vaccines, Adverse Effect, Epidemiology, China
- Trial name
- NCT05932563
- Where
- 6 sites in China
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Fujian Maternity and Child Health Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.